Abstract
GENENTECH PLANS TO INcrease its manufacturing muscle with the acquisition of a just-built biopharmaceutical plant in Oceanside, Calif, from rival Biogen Idee. The purchase, for about $408 million in cash, will increase Genentech's bioreactor capacity by 35% and reinforce its role as the world's largest biologies manufacturer. For Biogen, the sale is yet more fall-out from the voluntary withdrawal of the multiple sclerosis treatment Tysabri in February after a patient in a clinical trial died of a rare neurological disease. iogen had high hopes for the drug, which FDA approved last fall under an accelerated approval process, and expected to make it in the California plant. But following the withdrawal, the company says it can meet its foreseeable production needs from existing facilities in Cambridge, Mass., and Research Triangle Park, N.C. Genentech plans to use the plant to make the cancer treatment Avastin, which FDA approved in February 2004. Genentech anticipates ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
